Artificial Intelligence in Regenerative Medicine Market by Technology, Offering, Application, End-User

Description

List of Tables

[196 Pages Report] The Artificial Intelligence in Regenerative Medicine Market size was estimated at USD 59.63 million in 2023 and expected to reach USD 72.38 million in 2024, at a CAGR 22.05% to reach USD 240.63 million by 2030.

Global Artificial Intelligence in Regenerative Medicine Market

KEY MARKET STATISTICS
Base Year [2023]	USD 59.63 million
Estimated Year [2024]	USD 72.38 million
Forecast Year [2030]	USD 240.63 million
CAGR (%)	22.05%

Artificial Intelligence in Regenerative Medicine Market - IMG1

Artificial intelligence (AI) is increasingly important in regenerative medicine as it is a multidisciplinary approach to repairing, replacing, or regenerating damaged or lost tissues and organs within the human body. AI technologies are applied to various aspects of regenerative medicine to accelerate research, enhance patient care, and improve treatment outcomes. The AI in the regenerative medicine market encompasses integrating AI technologies such as machine learning algorithms, deep learning systems, natural language processing tools, and robotics with stem cell therapy, tissue engineering, immunotherapies, and gene editing techniques. Increased funding for research & development activities in both public and private sectors has accelerated the adoption of advanced technologies such as AI. Additionally, the rising prevalence of chronic conditions such as cancer and cardiovascular diseases has increased demand for innovative treatment approaches that can only be met through groundbreaking solutions provided by AI-enabled regenerative medicine, further increasing market growth. However, data privacy concerns arise due to the sensitive nature of patient information used for training AI algorithms, and the complex algorithms used by AI systems hamper market adoption. The advent of personalized therapy and advances in next-generation sequencing (NGS) technologies have generated vast amounts of data requiring sophisticated analysis methods; this poses yet another opportunity for AI's application within the regenerative medicine landscape.

Regional Insights

The Americas hold a significant landscape in the artificial intelligence in regenerative medicine market owing to significant investments and partnerships and the presence of key market players continuously focusing on innovations in the market. Additionally, the government initiative brings together researchers from various fields who focus on integrating AI technologies to develop novel therapeutic approaches for organ regeneration and repair. In the European Union, funding programs such as Horizon 2020 have allocated substantial resources to advance AI-based regenerative medicine projects. The government has launched several projects to map every human cell type using machine learning algorithms, further fueling the region's market adoption. APAC region is rapidly advancing in AI-based regenerative medicine, backed by significant government investments. Leading companies have established dedicated healthcare units that apply AI technologies to medical issues, including regenerative therapies. The government has also launched strategic initiatives to develop AI technologies for regenerative medicine to support industries such as healthcare and biotechnology, further fueling market adoption in the region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Artificial Intelligence in Regenerative Medicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Artificial Intelligence in Regenerative Medicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Artificial Intelligence in Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include Cognetivity Ltd., F. Hoffmann-La Roche Ltd., Intel Corporation, Medtronic PLC, Merck KGaA, Microsoft Corporation, NANO-X IMAGING LTD., Novo Nordisk A/S, NVIDIA Corporation, Sanofi SA, Tempus Labs, Inc., and Wipro Limited.

Market Segmentation & Coverage

This research report categorizes the Artificial Intelligence in Regenerative Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Computer Vision
- Context-Aware Computing
- Machine Learning
- Natural Language Processing
Offering
- Hardware
  - Memory
  - Network
  - Processor
- Services
- Software
Application
- Cybersecurity
- Drug Discovery
- Fraud Detection
- Healthcare Assistance Robots
- Medical Imaging & Diagnostics
- Patient Data & Risk Analysis
- Precision Medicine
End-User
- Healthcare Payers
- Hospitals & Providers
- Pharmaceutical & Biotechnology Companies
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Artificial Intelligence in Regenerative Medicine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Artificial Intelligence in Regenerative Medicine Market?

3. What are the technology trends and regulatory frameworks in the Artificial Intelligence in Regenerative Medicine Market?

4. What is the market share of the leading vendors in the Artificial Intelligence in Regenerative Medicine Market?

5. Which modes and strategic moves are suitable for entering the Artificial Intelligence in Regenerative Medicine Market?

Product Code: MRR-A6768A62EE04

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Artificial Intelligence in Regenerative Medicine Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of chronic and rare diseases
  - 5.1.1.2. Growing consumer preference for precision medicines and stem cell therapies
  - 5.1.1.3. Supportive government initiatives for deployment of AI in healthcare sector
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with AI-based solutions for regenerative medicine
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in technologies for improved drug discovery and development
  - 5.1.3.2. Rising funding and investments for deployment of AI
- 5.1.4. Challenges
  - 5.1.4.1. Concerns regarding data privacy coupled with limited availability of skilled professionals
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Significant adoption of computer vision technology for accurate and efficient detection of key biological structures
- 5.2.2. Offering: Hardware provides the necessary computational power in AI applications in regenerative medicine
- 5.2.3. Application: Potential utilization of AL technology in drug discovery applications
- 5.2.4. End-User: Pharmaceutical and biotechnology companies focus on leveraging AI to accelerate drug discovery
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Artificial Intelligence in Regenerative Medicine Market, by Technology

6.1. Introduction
6.2. Computer Vision
6.3. Context-Aware Computing
6.4. Machine Learning
6.5. Natural Language Processing

7. Artificial Intelligence in Regenerative Medicine Market, by Offering

7.1. Introduction
7.2. Hardware
- 7.3.1. Memory
- 7.3.2. Network
- 7.3.3. Processor
7.3. Services
7.4. Software

8. Artificial Intelligence in Regenerative Medicine Market, by Application

8.1. Introduction
8.2. Cybersecurity
8.3. Drug Discovery
8.4. Fraud Detection
8.5. Healthcare Assistance Robots
8.6. Medical Imaging & Diagnostics
8.7. Patient Data & Risk Analysis
8.8. Precision Medicine

9. Artificial Intelligence in Regenerative Medicine Market, by End-User

9.1. Introduction
9.2. Healthcare Payers
9.3. Hospitals & Providers
9.4. Pharmaceutical & Biotechnology Companies

10. Americas Artificial Intelligence in Regenerative Medicine Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Artificial Intelligence in Regenerative Medicine Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Artificial Intelligence in Regenerative Medicine Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
  - 13.3.1.1. Axolotl Biologix and Carmell Therapeutics Enter Merger Deal
- 13.3.2. Agreement, Collaboration, & Partnership
  - 13.3.2.1. Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
  - 13.3.2.2. Wipro and Pandorum Partner to Accelerate Regenerative Medicine with Artificial Intelligence

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Cognetivity Ltd.
- 14.1.2. F. Hoffmann-La Roche Ltd.
- 14.1.3. Intel Corporation
- 14.1.4. Medtronic PLC
- 14.1.5. Merck KGaA
- 14.1.6. Microsoft Corporation
- 14.1.7. NANO-X IMAGING LTD.
- 14.1.8. Novo Nordisk A/S
- 14.1.9. NVIDIA Corporation
- 14.1.10. Sanofi SA
- 14.1.11. Tempus Labs, Inc.
- 14.1.12. Wipro Limited
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing